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prednisone, 20 mg twice daily. Azathioprine was withheld because of
the moniliasis.
Following four days of therapy with ketoconazole, the patient be-
came increasingly weak. She was unable to easily ingest fluids or food,
and she lost 3 to 4 pounds in the 4 days before being referred for
admission to the UCSF Medical Center (Moffit Hospital). Table 1
contains details of the patient's clinical course and followup. Note
particularly the extremely high cyclosporine trough levels on admis-
sion. The patient's acute renal transplant dysfunction responded
promptly to a significant reduction of the oral cyclosporine dose.
Eventually, the dose of cyclosporine needed by the patient was 10% of
that needed prior to ketoconazole administration. The clinical course
subsequent to cessation of ketaconazole and reinstitution of cyclospo-
rifle, 80 mg twice daily, has been uneventful; the serum creatinine has
remained stable at approximately 1.4 mg/dl.
Discussion
Case presentation
An 18-year-old woman was admitted to a local hospital with acute
renal failure one year after receiving a one-haplotype, parent-donated
renal allograft. The patient's original renal failure had been due to
chronic pyelonephritis. Over the first year after transplantation, she had
had a stable medical course; her immunosuppressive medications
gradually were tapered to prednisone, 12.5 mg/day; azathioprine, 50
mg/day; and cyclosporine (CSA), 100 mg twice daily. Over the year, the
serum creatinine values had ranged from 1.4 to 1.6 mg/dl. Two weeks
prior to admission, the serum creatinine rose slightly, to 2.6 mg/dl. The
CSA levels were in the "therapeutic-range." Despite a urine culture
that was positive for E. coli, she was not thought to have pyelonephri-
tis; she was afebrile, the allograft was non-tender, the urinalysis
revealed only 4 to 6 white blood cells/high-power field, and a renal
sonogram was normal. A diagnosis of late acute transplant rejection
was made, and she was given 3 days of prednisolone in intravenous
pulses. The serum creatinine returned to a level of 1.5 mg/dl following
this treatment. Shortly thereafter, however, she developed severe
oroesophageal moniliasis. This superimposed illness was so severe that
ketoconazole therapy was initiated, 200 mg orally twice daily. The
cyclosporine dose was empirically reduced to 80 mg orally twice daily.
The patient was discharged receiving these two medications as well as
Presentation of the Forum is made possible by grants from Pfizer
Incorporated; Merck Sharp & Dohme International; Sandoz, Incorpo-
rated; Marion Merrell Dow Incorporated; and Amgen, Incorporated.
This Forum was held at the UCSF Medical Center (Moffit Hospital) in
San Francisco, California.
© 1991 by the International Society of Nephrology
DR. FELIX FREY (Professor of Medicine and Nephrology,
University Hospital of Berne, Inseispital, Berne, Switzerland):
The patient under discussion today illustrates well the practical
implications of the altered kinetics of cyclosporine and pred-
nisone in renal transplant patients. The inhibition of some
microsomal hepatic P-450 isoenzymes by ketoconazole sub-
stantially decreased the catabolism of cyclosporine and pred-
nisolone; this decreased catabolism in turn led to both excess
immunosuppression, as evidenced by the delayed response of
the moniliasis to the antifungal therapy, and to cyclosporine-
induced renal dysfunction. Knowledge of the mechanisms
accounting for altered kinetics of immunosuppressive agents
allows the clinician to calculate more appropriate doses ("dose
finding") in such patients. In this discussion, therefore, I will
review the determinants of the pharmacokinetics of cyclospo-
rifle and prednisone, delineate the pharmacodynamic relevance
of altered pharmacokinetics, and propose a strategy for optimal
dosing in patients with abnormal disposition of these xenobiot-
ics.
Cyclosporine
The gastrointestinal absorption of cyclosporine is slow and
incomplete [1—31. Peak concentrations in blood occur 1 to 8
hours after oral administration; the absorption half-life (assum-
ing first-order absorption) ranges from 0.6 to 2.3 hours [1—41.
The values of systemic availability vary with the method used
for measuring cyclosporine. In one of our studies in 58 renal
transplant patients, high-performance liquid chromatography
measurements of the systemic availability of cyclosporine were
25% lower than radioimmunoassay (RIA) measurements using a
polyclonal antibody (30% 13% versus 41% 14%) [31. This
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Table I. Clinical and laboratory data from Patient I
HPLC
Serum CSA CSA trough
Wt Hct creatinine BUN Prednisone dose level Ketoconazole
Date (kg) (%) (mg/dl) (mg/dl) (mg/day) (mg) (ng/ml) (mg/day)
Baseline 50.0 28 1.4—1.6 30 12.5 100 BID 174—196 —
6/19 50.0 — 1.5 — 40 80 BID 174 400
6/23 48.0 28 3.4 — — — — 400
6/24 48.6 28 4.2 110 40 5OQD — 400
6/25
6/26
—
—
26
—
Renal ultrasound (admission)—normal
morphology + normal Doppler
Renal scan—good uptake, slightly delayed
excretion
3.6 113 40
3.1 109 40
Held
50
825
—
400
400
6/27 49.2 25 2.7 78 40 Held 866 400
6/28 — 27 2.6 59 40 Held — 400
6/29
7/1
—
48.8
—
—
— — 40
2.4 50 40
50Q
3 days
—
—
190
400
400
7/6
7/13
.—
—
—
—
2.2 — 40
— — 40
50Q
3 days
80 BID
178
—
400
400
7/16 — — 1.9 — 40 80 BID 120 —
7/31 46.8 — 1.4 25 15 80 BID 112 —
a HPLC = High-performance liquid chromatography; the "therapeutic" trough level at one year post transplant ranges from 100 nglml to 250
nglml.
difference in bioavailability is due to the fact that a fraction of
oral cyclosporine absorbed from the gut is converted during its
first passage through the gut wall or liver into metabolites that
react with the polyclonal antibody used in the RIA technique,
but are not detected by the more specific high-performance
liquid chromatography method.
Gastrointestinal absorption of cyclosporine depends on three
factors. The first is the coad ministration of food (Table 2). After
an oral dose of cyclosporine, the area under the concentration-
versus-time curve of cyclosporine is about 60% higher when the
drug is given with food than without food [5]. The mechanism
by which eating enhances the absorption of cyclosporine is
unknown. It is likely, however, that it is related to gallbladder
contraction following the intake of food because the second
determinant of cyclosporine absorption is bile. Cyclosporine is
lipophilic; a bile deficit therefore impairs its absorption. This
phenomenon has been demonstrated in liver transplant patients
by insertion of a T-tube into the common bile duct for external
bile drainage. Clamping of the biliary T-tube greatly improves
the absorption of cyclosporine; the delivery of bile into the gut
likely is the cause of the increased absorption [61. Preliminary
investigations suggest that the exact location of the delivery of
bile into the gut is crucial. In pediatric liver transplant patients
with a Roux-en-Y biliary enterostomy, bile and cyclosporine do
not mix until they reach the distal small gut, where cyclosporine
is malabsorbed [7]. Only a negligible fraction of oral cyclospo-
rine reaches the systemic circulation by the lymphatic vessels.
The third determinant of cyclosporine absorption appears to be
gastrointestinal function. Bone marrow transplant recipients
with diarrhea (due to radiation therapy, graft-versus-host dis-
ease, or infectious enteritis), 20% to 30% of patients with
inflammatory bowel disease, and patients with a short bowel
syndrome all have lower-than-anticipated blood levels after
receiving an oral dose of cyciosporine [8—i 1]. Metoclopramide
Table 2. Factors affecting the kinetics of cyclosporine
Total-
Factor
body
clearance
Gastrointestinal
absorption Reference
Liver failure a j. 32, 55, 60
Bile deficit — 6
Diarrhea —* . 8—11
Food intake
Renal failure
—*
(J, )b
j'(J,)
5
55, 62, 63
Children —* 32, 61
Elderly subjects —*
Inhibitors of P-450 (f) 37—40, 43, 44, 47—50
51, 52
Calcium-channel-
blocking
agents
(diltiazem,
nicardipine,
verapamil)
Ketoconazole
Erythromycin
Inducers of P-450 (i,) 30—33
Phenytoin
Barbiturates
Carbamazepine
Rifampicin
a Diminished clearance or absorption; —*: unchanged clearance or
absorption; t: increased clearance or absorption.b Unknown. The arrow in parentheses indicates the changes one
might predict.
increased the mean area under the blood concentration-versus-
time curve of cyclosporine after oral dosing by 30% in 14
patients; gastric motility thus might be relevant for the absorp-
tion of cyclosporine [12]. Finally, the systemic availability of
oral cyclosporine increases during the first weeks after kidney
transplantation for unclear reasons [13].
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Cyclosporine undergoes extensive metabolism, predomi-
nantly in the liver [14], and metabolites are found in both bile
and urine [15]. Virtually no unchanged cyclosporine is detect-
able in the urine. The biotransformation pathway of cyclospo-
rifle is similar in various animal species [16]. Whereas the cyclic
oligopeptide structure of cyclosporine seems to be conserved,
structural alterations during metabolism comprise mono- and
dihydroxylation as well as oxidative N-demethylation (Fig. 1).
In human hepatic microsomal preparations, the degradation of
cyclosporine to its metabolites is NADPH dependent and can
be inhibited by ketoconazole (as in the patient presented today),
monoxide, and SKF 525A [14]; cyclosporine's metabolism thus
might be mediated mainly through the multiple mono-oxygen-
ase forms of cytochrome P.450.
At least 16 microsomal P-450 genes are expressed in humans
[17]. The isoenzyme responsible for the major part of cyclospo-
rine metabolism recently was identified by studying the me-
tabolism of cyclosporine in rabbit liver microsomes [18].
Microsomes from phenobarbital-, beta-naphthofiavone-, tn-
acyloleandomycin-, erythromycin-, or nifampin-treated and un-
treated rabbits were investigated; only microsomes from ani-
mals given the macrolide antibiotics (triacyloleandomycin or
erythromycin, known to be specific inducers of form P-450 3c)
exhibited a type-l binding spectrum on cyclosporine addition
and extensively metabolized the drug to all groups of deriva-
tives [18]. The binding spectrum is an expression of a positive
interaction between P-450 and its substrate. A linear correlation
was found between cyclosporine oxidase activity and the
specific content of P-450 3c. Antibodies to P-450 3c strongly
inhibited cyclosporine oxidase activity of induced microsomes,
whereas antibodies to other forms of P-450 did not. When
highly purified forms of P-450 were assayed in a reconstituted
system, only P-450 3c exhibited a type-i binding spectrum on
cyclosporine addition and extensively metabolized the drug to
all derivatives [18]. The finding that P-450 3c is extensively
involved in the formation of all derivatives of cyclosponine
identified thus far is surprising, because it is well established
that P-450 forms exhibit broad and overlapping substrate spec-
ificities [17].
Fig. 2. Formation of the three primary metabolites of cyclosporine in
microsomes of 15 human livers from renal transplant donors and
Western blots of microsomal protein (apparent mR 52000) recognized
by monoclonal antibody 13-7-JO. The Ml, M17, and M21 refer to
individual metabolites of cyclosporine; the numbers at the bottom
identify individual livers. (From Ref. 19.)
The P-450 3c found in rabbits appears to be homologous with
the P-450111 gene family in humans. Antibodies against P-450111
in hepatic microsomes obtained from kidney transplant donors
abrogated the formation of two monohydroxylated metabolites
(Ml and Ml7) and of the demethylated metabolite (M2l) [19].
These—MI, M17, and M2l—are the three primary in-vivo
metabolites of cyclosporine that are further metabolized by
subsequent P.450-catalyzed reactions [20]. The conclusion that
the P450111 gene family in humans accounts for hepatic mi-
crosomal cyclosporine metabolism is supported by the correla-
tion between the immunoquantitation of the protein recognized
by the monoclonal antibody reacting with the human P-450111
gene family and the metabolism of cyclosporine in the corre-
sponding human hepatic microsomes (Fig. 2) [19].
The P-450 isoenzymes are inducible by specific xenobiotics
CH3 H
CH-CH2''C(S) AA9
CH3
Fig. 1. Structural formula of cyclosporine A.
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[171. The increased amount and activity of isoenzymes observed
following induction is attributable to an increased de-novo synthe-
sis of protein, not to an impaired breakdown [21]. For some
isoenzymes, it was shown that the increased synthesis is due to an
increased transcription [22, 23]. Phenobarbital, one of the most
carefully investigated inducers of P-450, induces several different
mRNAs for the synthesis of various cytochrome P-450 isoen-
zymes [231. How phenobarbital activates transcription of these
genes and how the differential induction of some but not all P-450
isoenzymes is achieved is not known [241. It has been proposed
that induction is mediated via an intracellular receptor, as shown
for polycyclic aromatic hydrocarbon- and steroid-responsive
forms of cytochrome P-450 [25, 26]. Such a receptor has not been
found, however. An alternative hypothesis is that the isoenzymes
themselves are the receptors [24]. This concept is supported by
the observations that first, many ligands and inhibitors of cy-
tochrome P-450 are good inducers, and second, inducers reach
high intracellular concentrations and are substrates of phenobar-
bital-induced cytochromes P-450 [27—291.
The relationship between the induction of hepatic P-450
isoenzymes and cyclosporine metabolism has been investigated
in rats [30]. The administration of phenobarbitone together with
cyclosporine decreased cyclosporine blood concentrations and
prevented cyclosporine nephrotoxicity, assessed both biochem-
ically and histologically. These findings in rats are in line with
observations made in humans. In 6 healthy volunteers, admin-
istration of phenytoin for 9 days reduced the mean plasma
concentration-versus-time curve ("area under the curve") after
administration of oral cyclosporine by about 50% (Table 2) [31].
Cyclosporine was not given intravenously in this study, so it is
unknown to what extent the reduction in blood levels was due
to an increased metabolic clearance rate, first-pass metabolism,
or decreased absorption of cyclosporine. Decreased concentra-
tions of cyclosporine also were reported for a small number of
patients treated with other agents known to induce hepatic
microsomal enzymes, such as phenobarbitone, carbamazepine,
rifampicin, and possibly isoniazid [32, 33]. Rigorous quantita-
tive data concerning the effects of these agents on cyclosporine
concentrations are not available.
The P-450 isoenzymes responsible for the formation of the
primary metabolites of cyclosporine also are responsible for the
metabolism of some calcium-channel blocking agents [29, 34].
These agents frequently are prescribed to renal transplant
patients, because more than 70% of these patients are hyper-
tensive. Moreover, there is some evidence for a slight protec-
tive effect of calcium-channel blocking agents on posttransplant
acute tubular necrosis in patients treated with cyclosporine [35,
36]. This explains the interest in the study of the interaction
between calcium-channel blocking agents and the kinetics of
cyclosporine.
Cross-sectional analysis of dose and trough levels of cyclo-
sporine in a total of 160 patients receiving or not receiving
diltiazem revealed that a 20% to 50% reduction in the dose of
cyclosporine was required to achieve comparable blood con-
centrations of cyclosporine when the patients were given dii-
tiazem together with cyclosporine. This finding was confirmed
in a crossover trial with 22 additional patients [37, 381. Initiation
and discontinuation of nifedipine had no effect on trough levels
of cyclosporine in 22 renal transplant patients [37], whereas
earlier individual case reports had suggested that verapamil and
Cyclosporine dose, mg/kg/day
Fig. 3. Cyclosporine dose-response curves for the suppression of de-
layed hypersensitivity response. Dose of cyclosporine versus percent-
age of maximal immunosuppression is shown for animals treated
concurrently with ketoconazole vehicle (•) or with 100 mg/kglday of
ketoconazole (0). Standard error of the mean is shown. Both curves
originate at 0% immunosuppression. (From Ref. 50.)
nicardipine inhibited the metabolism of cyclosporine in such
patients [39, 40]. It is not surprising that all calcium-channel
blocking agents do not inhibit the metabolism of cyclosporine
because, besides structural differences, local concentrations
and affinity for the active site at the P-450 isoenzymes may
differ among the various calcium-channel blockers [17].
In addition to the pharmacokinetic interaction, there is also a
pharmacodynamic interaction between some calcium-channel
blocking agents and cyclosporine. Verapamil inhibits T-cell
activation and by that mechanism synergistically enhances the
immunosuppressive effect of cyclosporine [41, 42]. To what
extent this effect is clinically relevant is unknown, however.
Practically, it is reassuring to know that reducing the dose of
cyclosporine (to obtain an appropriate concentraUon of cyclo-
sporine) in patients treated with verapamil might increase rather
than decrease the overall immunosuppressive effect.
A similar pharmacodynamic and pharmacokinetic interaction
exists between cyclosporine and ketoconazole (see also the
discussion about steroids). Ketoconazole, an imidazole deriva-
tive, is a potent inhibitor of many P-450 isoenzymes, including
the one responsible for the metabolism of cyclosporine, and it
also inhibits many T-cell functions [43—46]. When ketoconazole
is added to a cyclosporine regimen, increased concentrations of
cyclosporine result in rats, mice, and humans [43, 44, 47—50].
These increased concentrations of cyclosporine in mice are due
to a decreased metabolic clearance rate of cyclosporine [49].
The decreased metabolic clearance of cyclosporine is pharma-
codynamically relevant [50]. The dose of cyclosporine that
produces 50% of the maximal immunosuppression for cyclo-
sporine is 2.5 times lower when cyclosporine is given together
with ketoconazole in mice (Fig. 3). In addition, toxicity—as
measured by the death of the animals (mostly because of
infection)—is increased in animals receiving both drugs [50]. In
rats the increased concentrations of cyclosporine that result
from the coadministration of ketoconazole increased cyclospo-
rine-associated nephrotoxicity [47]. Thus, the combination of
abnormally high cyclosporine blood levels, decreasing renal
function, and lack of response of the fungal infection in the
patient presented are expected findings.
An interaction between erythromycin and cyclosporine has
100
50
0
00
• Ketoconazole vehicle
0 100 mg/kg/day Ketoconazole
0 25 40 80 100
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,I,t l,t
Final therapeutic Biologic Drug concentration
objective intermediate
therapeutic objective
been reported repeatedly [511. Because erythromycin inhibits
the P-450 isoenzymes, it is likely that the increased concentra-
tions of cyclosporine observed when erythromycin is given
together with cyclosporine are due to a decreased catabolism of
cyclosporine. However, an increased absorption of cyclospo-
rine also has .been suggested as the underlying mechanism [521.
Methyltestosterone, danazol, oral contraceptive steroids, and
high doses of methylprednisolone all have been reported as
increasing blood levels of cyclosporine [32, 51], but these
scattered case reports are not conclusive,
Target concentration strategy for the dose finding of cyclo-
sporine? There are three models for dose finding; unfortunately,
none is ideally suited for dose finding of cyclosporine in clinical
practice (Table 3). The most efficient method is adjustment of a
drug dose according to the final therapeutic objective, as when
a patient with headache is treated with paracetamol. This model
is inappropriate for cyclosporine as it is whenever the failure to
reach the therapeutic end point or the occurrence of side effects
due to overtreatment is perilous. In such situations, the second
method, namely the definition of an intermediate therapeutic
objective, often improves the dose-finding process. The inter-
mediate therapeutic objective can be either a target drug level
or some biologic measure. An example of the latter is the
determination of the prothrombin tithe in a patient receiving
warfarin for pulmonary emboli; in this situation, titration of the
dose according to the final therapeutic objective (prevention of
emboli) and the side effect (bleeding) would be an inefficient
way of adjusting the dose. Although conceptually it should be
possible to define, a biologic intermediate therapeutic objective
for immunosuppressive therapy in renal transplantation, this is
not yet feasible. Recently, measurements of cyclosporine level
(as an alternative, intermediate therapeutic objective in renal
transplantation) were advocated, a dose-finding strategy useful
for many other drugs in modern clinical practice. In the patient
under discussion, dosage adjustments, in fact, were made
according to blood levels of cyclosporine. Thus, the question
arises as to what extent cyclosporine fulfills the criteria for a
meaningful application of such a 'target concentration", strat-
egy. Six criteria have been identified [53], only the first four of
which are met by cyclosporine: (1) The drug must exhibit a wide
interindividual variability in absorption and elimination. Cy-
closporine certainly meets this criterion, as illustrated with
regard to clearance in Figure 4 [54, 55]. (2) The time to reach the
true therapeutic objective (years of successful renal function, in
the case of cyclosporine) and the time when side effects appear
should be long after the time of the therapeutic intervention.
This is the case when cyclosporine is used to prevent renal
allograft rejections. (3) The therapeutic index must be narrow.
Most patients with trough whole-blood cyclosporine concentra-
tions above 700 nglml (measured by the first-generation poly-
Fig. 4. Blood clearance of cyclosporine (CyA) calculated by using
whole blood concentrations assessed by high-performance liquid chro-
matography in stable renal transplant patients one month and one year
after transplantation. The clearance value declined in the course of the
first year of successful renal transplantation in 19 of 28 patients. (From
Ref. 54.)
clonal antibody) experience side effects [56, 57]. The definition
of a clinically efficacious concentration is more controversial,
and no useful experimental data are available. Many clinicians
agree that concentrations between 200 and 600 ng/ml are
efficacious when cyclosporine is given either alone or with a low
dose of prednisone. Thus, it is likely that the therapeutic index
of cyclosporine is indeed narrow, an assumption also supported
by a recent study in mice [50]. (4) The therapy must maintain a
constant effect over a long time. Cyclosporine therapy also
fulfills this criterion for a target concentration strategy. (5) The
concentration of the drug in blood must be directly related to its
effect. Concentration-effect curves between cyclosporine levels
and inhibition of lymphocyte functions have been established in
vitro. In clinical renal transplantation, however, even rough
estimates between cyclosporine concentrations and the likeli-
hood of rejection are missing. Thus, this prerequisite is not met
for cyclosporine; future studies in this area are required. (6) The
measurements of the drug concentrations should be specific and
the individually measured blood concentration representative
for the time-averaged concentration in a given individual. This
is probably not the case for cyclosporine for two reasons. First,
Table 3. Strategies for dose finding 9,7 12,9
a)
C)C
a)
Ca
a,
C)0
8
8
7
6
5
4
3
0 I I
1 month 1 year
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Trough Iev& (RA), ng/ml
Fig. 5. Relation between trough levels and areas under the curve
(AUCs) assessed by radioimmunoassay after oral cyclosporine, The
relationship was established for trough levels assessed 720 and 1440
minutes after administration and the corresponding AUCs. Similar
coefficients of determination (r2) were obtained when the AUCs after
oral or intravenous dosing were measured by high-performance liquid
chromatography. The values of the r2 were consistently lower when the
trough levels were assessed 720 than 1440 minutes after administration.
This finding indicates that trough levels measured at 720 minutes poorly
reflect the exposure of the body to cyclosporine. (From Ref. 3.)
the various antibodies available detect different metabolites
together with the parent compound, whereas the specific high-
performance liquid chromatography method detects only the
parent compound [58]. Because we do not know which of the
compounds are responsible for efficacy and which for side
effects, selection of the appropriate method for determining the
concentrations remains problematic. Second, trough levels
correlate poorly with the corresponding areas under the con-
centration-versus-time curves (AUC) for the corresponding
dosing interval, indicating that trough levels offer only an
incomplete reflection of the body's exposure to cyclosporine
(Fig. 5) [3]. Because of this shortcoming, Grevel, Welsh, and
Kahan recently proposed that cyclosporine be measured by
determination of AUC values instead of trough levels, an
approach not applicable at most institutions [591.
Thus cyclosporine does not fulfill these last two important
prerequisites for a target concentration strategy. This defi-
ciency explains the limited utility of using blood concentrations
of cyclosporine for dose finding in clinical practice at present,
unless they are used to detect a grossly abnormal disposition of
cyclosporine (as in the patient discussed here). Despite these
limitations, measuring blood concentrations of cyclosporine
remains clinically relevant, especially in monitoring compli-
ance, the most important variable of drug efficacy in outpa-
tients.
Prednisolone/prednisone
Prednisolone is by far the most active immunosuppressive
steroid when prednisolone or its in-vivo interconvertible 11-
keto metabolite, prednisone, is administered [64]. Thus, kinetic
studies should assess specific prednisolone concentrations in
biologic fluids. Because patients treated chronically with a
moderate dose of prednisone continue to secrete endogenous
cortisone and cortisol [65], specific high-performance liquid
chromatographic methods had to be developed to distinguish
prednisolone both from prednisone and from its other metabo-
lites and from endogenous glucocorticoids [66—68]. Pred-
nisolone exhibits nonlinear binding to albumin and transcortin,
with a free fraction ranging from less than 0.1 to 0.5 [69, 70].
The concentrations of these binding proteins are affected by
hepatic and renal diseases and by the concomitant administra-
tion of estrogens [71, 72]. Given that the unbound species of
prednisolone probably accounts for its biologic effect [73, 74],
kinetic investigations have to focus on the unbound, rather than
on the total, concentration of prednisolone.
Prednisolone and prednisone are interconvertible, and pred-
nisolone is given intravenously as a water-soluble phosphate or
hemisuccinate or tetrahydrophthalate prodrug. Thus, values of
clearance and volume of distribution, derived from pred-
nisolone concentration measurements in plasma, reflect only
apparent values of these parameters. When calculated with
reference to total prednisolone concentrations in plasma, the
values of total-body clearance and volume of distribution in-
crease with increasing doses of prednisolone administered, an
observation made by our group and several groups of investi-
gators, using different models for calculating the kinetic param-
eters [75—78]. Part of the dose-dependent clearance of pred-
nisolone is explained by the concentration-dependent protein
binding; that is, at high doses, the increased free fraction of
prednisolone is reflected in a greater plasma clearance and
apparent volume of distribution. The relevance of protein
binding for the dose-dependency of prednisolone kinetics is
supported by the observation that subjects exhibiting an abnor-
mally high binding of prednisolone to plasma proteins (for
example, women taking estrogen-containing oral contraceptive
steroids) have decreased values of total-body clearance and
volume of distribution of total prednisolone, whereas subjects
exhibiting an abnormally low binding of prednisolone to plasma
proteins (such as nephrotic patients) have increased values of
total-body clearance and volume of distribution of total pred-
nisolone [79—821.
In addition to the concentration-dependent plasma protein
binding, the concentration-dependent clearance of unbound
prednisolone also might account for part of the dose-dependent
clearance of total prednisolone. This phenomenon was demon-
strated by Legler et al, who showed that the total-body clear-
ance of unbound prednisolone under steady-state conditions in
normal volunteers is 30% higher after a high- than after a
low-infusion rate [78]. The increase in total-body clearance of
unbound prednisolone with increasing dose is probably due to
an increase in renal and non-renal clearance [83]. The dose-
dependent renal clearance cannot be explained by a dose-
dependent impact of the corticosteroid on the glomerular filtra-
tion rate, because the ratios of the renal clearance of total or
unbound prednisolone to the creatinine clearance (fractional
renal excretion) are higher after a dose of 0.8 mg/kg than after
a dose of 0.2 mg/kg of prednisolone [83].
After a low dose of 0.2 mg/kg of intravenous prednisolone,
the ratio of the AUC for prednisolone over prednisone was 7,
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Table 4. Factors affecting the kinetics of prednisolone/prednisone
Apparent
total-body Gastrointestinal
Factor clearance absorption Reference
Liver failure a 97
Chronic renal failure ? (.) 92, 93
without a transplant
Renal transplant patients — 54
Hyperthyroidism f 88
Inflammatory bowel —* — 87
diseases
Elderly subjects (65 yrs) I —* 90
Subject taking:
Estrogen-containing I — 80, 81
contraceptive steroids 113, 114
Ketoconazole I —p 89
Carbimazole or ? 120, 121
methimazole
Phenytoin ' -+ 118, 119, 125
Barbiturates t ? 115, 126
Rifampin ? 116, 130
Carbamazepine (1) ? —
Some brands of enteric- —+ 1 87
coated prednisolone
I.V. prednisolone — 84, 138
tetrahydrophthalate
a Arrows are explained in Table 2.
whereas after a high dose of 7 mg/kg, this ratio was more than
66 in renal transplant patients [83, 841. This finding suggests an
apparent concentration-dependent interconversion between
prednisolone and prednisone in favor of the former species.
When very high doses of intravenous prednisolone or of oral
prednisone (7 mg/kg) are given, prednisone concentrations
appear to approach a maximum of only about 50 ng/ml to 60
ng/ml. The nonlinear relationship between the plasma concen-
trations of prednisolone and prednisorie can be described by a
Michaelis-Menten-type equation [78, 851. The reason for the
apparent shift of the plasma concentration ratios of pred-
nisolone/prednisone towards prednisolone with increasing ste-
roid doses is unknown [86].
As a consequence of the complex pharmacokinetics of pred-
nisolone, accumulation of knowledge about the factors affecting
the metabolism of this steroid has been slow [87]. The known
mechanisms accounting for the altered kinetics of prednisolone
are summarized in Table 4. Probably because of a short
intestinal transit time, patients with inflammatory bowel disease
[871 or hyperthyroidism [881 exhibit a decreased absorption of
prednisolone. Some brands of enteric-coated prednisolone tab-
lets are not absorbed or are only erratically absorbed in the
gastrointestinal tract; such enteric-coated tablets therefore
should not be administered to renal transplant patients [871.
The renal excretion of prednisolone is complicated and only
partly understood. There is evidence that the renal clearance of
total and unbound prednisolone increases with increasing dose
[83]. After an intravenous dose of 0.8 mg/kg of prednisolone
sodium phosphate, about 25% to 30% of the dose is recovered
in urine as unchanged prednisolone, as opposed to only about
12% when an equimolar dose of oral prednisone is given [89,
90]. The percentage of a prednisolone dose excreted as pred-
nisone is 2% to 5%. These higher values for the urinary
excretion of unchanged steroid are too low to explain the 67%
higher AUC values of unbound prednisolone after intravenous
prednisolone in 6 chronically uremic patients than in healthy
volunteers observed by Bergrem [91]. Oest et al found an
identical mean AUC of total prednisolone in 16 patients on
hemodialysis as in 6 healthy control subjects [92]. In the latter
study, no unbound concentrations of prednisolone were mea-
sured. Thus, no definitive conclusion about the effect of renal
function on the metabolism of prednisolone can be reached at
present.
In patients with renal failure, a renal transplant, or hyper-
parathyroidism, and in subjects older than 65 years or those
taking ketoconazole, the fraction of the dose of unchanged
steroid recovered in urine is reduced [54, 88—90, 93]. The
reduction is best explained in part by a diminished glomerular
filtration rate (except in the case of hyperthyroidism) and in part
by a reduced tubular secretion of prednisolone. The latter
mechanism is suggested by the observation that in healthy
volunteers the ratio between the renal clearance of unbound
prednisolone and the creatinine clearance is about 2. This
suggests tubular secretion of the steroid; this ratio was less than
one in the other groups I mentioned.
Lewis et al found that 37% of the patients with serum albumin
levels below 2.5 g/dl who were treated with prednisone experi-
enced corticosteroid-related side effects, compared with 15% of
those with serum albumin levels above 2.5 gJdl [94]. These
investigators hypothesized that the low albumin levels simply
might be a marker for impaired liver function (and thus impaired
metabolism of prednisolone), or that hypoalbuminemia could
directly cause increased free prednisolone levels, thereby re-
sulting in an increased frequency of side effects. To examine
this hypothesis, Bergrem and we administered intravenous
prednisolone or oral prednisone to nephrotic patients with low
protein concentrations and normal liver function [79, 82, 93].
Results showed decreased total, but normal unbound, concen-
trations of prednisolone in nephrotic patients when compared
with normal volunteers [79, 82, 93]. Thus, the association
between low albumin concentrations and increased incidence of
side effects is not causal in nature, as suggested [94, 95], but
rather exists because some patients have decreased albumin
concentrations due to impaired liver function [96] and that
impaired liver function is responsible for the diminished catab-
olism of prednisolone. A dosage adjustment of prednisolone
based on plasma protein concentrations as previously proposed
by Uribe and Go [951 is therefore wrong.
The systemic availability (that is, the ratio between the AUCs
after oral and intravenous dosing) of prednisolone after admin-
istration of oral prednisone or prednisolone is not reduced in
renal transplant patients [54, 77, 97, 98]. The values of renal and
non-renal clearance of prednisolone are diminished, however.
As a consequence, the mean total and unbound prednisolone
concentrations after oral and intravenous dosing were higher by
about 30% to 40% in 28 renal transplant patients treated with
cyclosporine than were levels observed in an equal number of
healthy volunteers (Fig. 6) [54]. The reduced prednisolone
clearance was not due to the administration of cyclosporine [97,
99]. When the results from the same 28 patients obtained at one
month and at one year after transplantation were compared, a
decline in the non-renal clearance of prednisolone, concomi-
tantly with a decline in the total-body clearance of cyclosporine
and galactose [541, was observed (Fig. 6). Thus the activity of
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Fig. 6. Plasma clearance of total prednisolone in 28 renal transplant
patients at one month and at one year after transplantation and in 28
healthy control subjects. The clearance declined during the first year of
transplantation in 22 of 28 patients (P < 0.001). Squares = patients
positive for hepatitis B markers; horizontal bars = the mean of the
respective population. (From Ref. 54.)
both microsomal (clearance of prednisolone and cyclosporine)
and cytosolic (galactose elimination capacity) liver enzymes
declined in the course of the first year of successful renal
transplantation. The decline in quantitative liver function was
not due to inhibition of liver enzymes by drugs. The mechanism
for the impaired liver function in these patients is unknown, but
the observation is in line with the fact that more renal transplant
patients die because of liver failure than do patients on dialysis
or a population of normal subjects [54].
Prednisolone has been used as a model compound to inves-
tigate the impact of nonlinear plasma protein binding on hemo-
dialysis clearance [1001. The hemodialysis clearance of total
prednisolone was concentration dependent (increasing from 0.4
mi/mm to 4.0 mI/mm), while the clearance of unbound pred-
nisolone was constant. With increasing total concentrations of
prednisolone in plasma, a relatively larger fraction of the total
plasma concentration was lost into the dialysate as a conse-
quence of nonlinear plasma protein binding. Interestingly, the
fraction of the dose of prednisolone administered that was lost
in the dialysate did not rise as the administered dose of
Controls prednisolone was increased. This was because the fraction of
• the total-body prednisolone content entering the dialyzer was
smaller as a consequence of the increased volume of distribu-
• tion with the increasing dose of prednisolone. Thus, pred-
nisolone exhibits concentration-dependent hemodialysis clear-
— ance but concentration-independent fractional removal of the
• dose. The fraction of the dose removed ranged from 7.0% to
• 17.5% during a 5-hour dialysis period, when the dose of
prednisolone was administered just prior to the initiation of
• dialysis. Thus, for practical purposes, the removal of pred-
nisolone by dialysis can be neglected.
The liver is the main organ for the catabolism of prednisolone
and for the conversion of prednisone to the biologically active
steroid prednisolone via reduction of the 1 l-oxo-group [86,
• 101]. This accounts for the studies of the impact of liver
function on such interconversion. Despite the impaired appar-
ent conversion of prednisone to prednisolone in patients with
• liver dysfunction, it is now clear that higher total and unbound
prednisolone concentrations are observed after administration
of oral prednisone in patients with impaired liver function [96].
This alteration occurs because the impaired conversion of
prednisone to prednisolone is balanced by a reduced metabolic
clearance of prednisolone in cirrhosis. The decreased metabolic
clearance of prednisolone is associated with a decline in the
fractional urinary excretion of 6beta-OH-prednisolone, indicat-
ing that the oxidative degradation of prednisolone is impaired,
whereas the formation of other metabolites (mostly glucuro-
nides) is preserved. This concept is in line with the established
scheme that the glucuronidation of drugs is largely maintained
in patients with advanced liver failure, while hydroxylation is
impaired [102—104].
The daily administration of 200 mg of ketoconazole inhibits
hepatic 6beta-hydroxylase activity, as assessed by the ratio of
urinary 6beta-OH-cortisol/1 7-OH-corticosteroid, or by the frac-
tional excretion of 6beta-OH-prednisolone (Fig. 7) [89]. The
decline in activity of the 6beta-hydroxylase is associated with
an impaired metabolic and renal clearance rate of prednisolone,
an unaltered apparent systemic availability of oral prednisone,
and an unchanged ratio of the AUCs of prednisolone/pred-
nisone. The mean AUC of unbound prednisolone after oral
prednisone increases by about 50% after ketoconazole. The
50% increased concentrations of free prednisolone in patients
receiving prednisone and chronic low-dose therapy with keto-
conazole are clinically relevant, because the increased immu-
nosuppressive effect of prednisolone is enhanced by the known
inhibitory effect of ketoconazole on T-lymphocyte functions
[45, 46]. Thus the concomitant administration of ketoconazole
and 40 mg of prednisone in the patient discussed here probably
resulted in prednisolone blood levels one would usually observe
in a patient given 80 mg of prednisone; direct measurements
would have been of interest. The combination of increased
prednisolone and cyclosporine concentrations no doubt ex-
plains the patient's increased susceptibility to infection.
Whether other imidazole derivatives structurally related to
ketoconazole and known to inhibit cytochrome P-450 oxidases
[105, 106] have a similar impact on prednisolone metabolism is
unknown. Cimetidine and ranitidine [106, 107], the macrolide
antibiotic troleandomycin [108], and cyclosporine A [97, 99], all
agents known to interfere with various mono-oxygenase sys-
tems in the liver, do not affect the metabolism of prednisolone.
Patients
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Fig. 7. Urinary excretion of 6f3-OH-prednisolone following intrave-
nous prednisolone before and after ketoconazole administration. (From
Ref. 89.)
Two studies of cyclosporine [110, 1111, disproved by more
recent investigations and criticized for methodologic reasons
[97, 99], had suggested an inhibitory effect of cyclosporine on
prednisolone metabolism.
Ethinyl derivatives of estrogens render the P-450 system
inactive, probably by covalent binding to prosthetic heme [112].
This effect explains the observation that in women taking oral
contraceptive steroids, the fraction of the metabolic clearance
of unbound prednisolone attributable to the formation of 6beta-
OH-prednisolone is abnormally low [81]. As a consequence of
the reduced catabolism, four independent groups of investiga-
tors found about 50% increased mean values of the AUCs of
unbound prednisolone in women taking oral contraceptives
concomitantly with prednisone or prednisolone [80, 81, 113,
114].
Several investigators have reported 30% to 50% lower plasma
concentrations of total prednisolone after induction of the
microsomal liver enzymes with phenytoin, barbiturates, carba-
mazepine, rifampin, or a combination of these agents [115—1 19].
During the administration of 300 mg/day of phenytoin for 6 to 8
days, protein binding, volume of distribution, and renal clear-
ance of prednisolone were unchanged, whereas the metabolic
clearance of unbound prednisolone increased by about 40%.
Concomitantly there was an increased urinary excretion of
6beta-OH-prednisolone, a finding indicating increased microso-
ma! liver enzyme activity [119].
In a cross-sectional study, Legler found about 50% lower
concentrations of unbound and total prednisolone in women
with Graves' ophthalmopathy treated with carbimazole or
methimazole than in women who had undergone thyroidectomy
for the same disease or in healthy female volunteers 1120, 121].
All patients were euthyroid and were treated with prednisone
for severe exophthalmos. Increased non-renal clearance of
prednisolone in hyperthyroid patients recently was observed in
a longitudinal study [88]. After treatment of hyperthyroidism,
AUCs of total and unbound prednisolone after oral prednisone
and intravenous prednisolone increased by about 40%. Induc-
tion or inhibition of microsomal liver enzymes changes the
fractional excretion of 6beta-OH-prednisolone and the non-
renal clearance of prednisolone in parallel [90, 119]. Interest-
ingly, this relationship did not hold when the non-renal clear-
ance of prednisolone was activated by thyroid hormones; that
is, hyperthyroid patients had an increased non-renal clearance
of prednisolone in the presence of a decreased fractional
excretion of 6beta-OH-prednisolone [88]. This result indicates
that thyroxine apparently inhibits some enzymes involved in
the metabolism of prednisolone while stimulating other en-
zymes. The concept that thyroxine exhibits a differential effect
on various liver enzymes is supported by animal and cell culture
studies [122—1241.
Evidence that altered kinetics of prednisolone are
pharmacodynamically relevant
First, we have shown in in-vitro studies that plasma samples
obtained from subjects treated with phenytoin and prednisone
inhibit mixed lymphocyte cultures less than do plasma samples
from the same subjects treated with prednisone only [125].
Similarly, the inhibition of mixed lymphocyte cultures after the
same dose of prednisone was more pronounced in euthyroid
than in hyperthyroid patients [88]. Second, in kidney and heart
transplantation studies performed in rats treated with pred-
nisolone or prednisolone plus phenobarbital, the organ survival
time was shorter in the animals with, than in those without,
induced microsomal liver enzymes (that is, in those receiving
phenobarbital) [126]. Third, Wassner et al [127, 128] and
Buffington et a! [129] presented circumstantial evidence that an
increased incidence of renal allograft rejection in humans
treated with azathioprine and prednisone was attributed to
anticonvulsants (barbiturates, phenytoin, carbamazepine) or
rifampin (Fig. 8). Given that 6-mercaptopurine, the active
moiety of azathioprine, is metabolized by xanthine oxidase, an
enzyme not inducible by the aforementioned xenobiotics, these
results suggest that the rejection episodes were mediated via
enhanced catabolism of prednisone. In a prospective study, Ost
et a! analyzed the relationship between the metabolic clearance
of total prednisolone after an oral test dose and the outcome of
the renal allograft [92]. These authors found that the frequency
of graft loss was higher in the group of patients with high than
in the group with low clearance values. Fourth, the addition of
rifampin to the drug regimen of prednisolone-treated patients
with asthma produced a measurable deterioration in the pa-
tients' clinical status and an improvement in the adrenocortical
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response to exogenous ACTH [130, 1311. Similar therapeutic
failures of steroid therapy have been reported for patients with
the nephrotic syndrome or rheumatoid arthritis after the admin-
istration of rifampin or barbiturates [117, 132].
When estrogens are given together with prednisone, the
increased unbound glucocorticoid concentrations most likely
account for the increased glucocorticoid effects. These are: (1)
increased inhibition of granuloma formation by hydrocortisone
in guinea pigs [132]; (2) increased glucosuric effect of pred-
nisolone in patients with diabetes [1341; (3) reduction of the
requirements of corticosteroids in various chronic inflammatory
skin diseases in an uncontrolled clinical setting [133]; and (4)
increased area under the inhibition-versus-time curve of mixed
lymphocyte reaction, a time-averaged measure of the immuno-
suppressive effect after a dose of prednisone [135] in healthy
women taking oral contraceptives [731.
After an intravenous dose of prednisolone phthalate, the
mean AUC of unbound prednisolone was only 45% of that
obtained after an equimolar intravenous dose of prednisolone
phosphate in 10 renal transplant patients [84]. These kinetic
differences were of biologic importance as evidenced by com-
paring the effect of these two prodrugs on the inhibition of
mixed lymphocyte cultures, of lymphocyte interleukin 2 re-
lease, or of the changes in the OKT4/OKT8 ratio in peripheral
blood [136].
Target concentration strategy for the dose finding of pred-
nisolone? Prednisolone fulfills several prerequisites for a "tar-
get concentration" strategy. First, there is a larger interindivid-
ual than intraindividual variability in prednisolone elimination
(Fig. 6) [54, 137]. Second, both prevention of allograft rejection
and serious side effects (osteopenia, aseptic bone necrosis,
cataract, infection) occur long after the point when one chooses
the dose of prednisolone. Third, the therapeutic index of
prednisolone is low. Fourth, the immunosuppressive effects of
prednisolone are directly related to its plasma concentration
[86]. Fifth, prednisolone is given to sustain a constant effect
over a long time in renal transplant patients. Sixth, sensitive
and specific assays for measuring prednisolone concentrations
and knowledge of average values of kinetic parameters are
available. Thus prednisolone meets many of the criteria neces-
sary for the target concentration strategy; yet such a strategy is
not applied at present for the following reasons: First, unbound
prednisolone concentrations are the relevant concentrations to
measure, but a suitable assay method is not available in most
laboratories. Second, because of the short half-life of pred-
nisolone, steady-state levels are not obtained at the usual daily
dosage (<50 mg/day). Thus either the entire AUC or a single
concentration in a plasma sample collected at a well-defined
time point after dosing would have to be analyzed. In addition,
the short half-life diminishes the utility of plasma concentration
measurements as a tool for the assessment of compliance.
Third prednisone is administered concomitantly with other
immunosuppressive agents, making the assessment of the ef-
ficacy of each agent, and therefore the definition of target
concentrations, difficult. Thus the target concentration strategy
cannot be applied for prednisolone.
How can the knowledge concerning variable prednisolone
metabolism be used for dose adjustment in clinical practice? We
tentatively propose the following strategy [87]: First, without
considering the metabolism of prednisolone, decide what dose
would usually be prescribed to a given patient with a certain
disease. This decision should be based on results from the
literature and from the clinician's individual experience.* Sec-
ond, consider whether the patient in question exhibits specific
features known to alter the metabolism of prednisolone; if so,
prescribe a modified dose according to the following rough
quantitative guidelines. Third, after having decided about the
initial dosage regimen, base further decisions entirely on de-
sired and undesired effects. Kinetic reasoning is warranted only
when factors known or suspected of influencing the metabolism
or the absorption of the steroid change subsequently. In the
patient discussed above, for instance, when a maintenance dose
* Note, it is probably unwise to consider features modulating the
metabolism of prednisolone in every patient with a certain disease state,
because in the decision for the a priori dose based on previous
experience, the impact of such metabolic abnormalities have already
implicitly been included [871.
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Fig. 8. Actuarial survival rates of grafts in patients
taking anticonvulsant medication (index patients)
versus grafts in control patients. (From Ref. 128.)
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of 40 mg of prednisone was considered adequate, that dose
might have been reduced to 20 mg after the addition of
ketoconazole.
The following factors influence the biologically relevant un-
bound concentrations of prednisolone and might be relevant for
rational prescription of prethiisone in clinical practice (Table 4):
(a) liver failure: increased prednisolone concentrations by
100% to 300% (depending on the residual liver function)
should be expected;
(b) chronic renal failure witllôut kidney transplant: 70%
increased concentrations after intravenous dose; oral
dose unknown;
(c) renal transplant patients: 70% increased concentrations
after oral dose;
(d) estrogen-containing oral contraceptive steroids: 50% to
100% increased concentrations;
(e) ketoconazole: 50% increased concentrations;
(./) old age (>65 years): 70% increased concentrations;
(g) hyperthyroidism: 40% decreased concentrations; euthy-
roid patients with exophthalmos on carbimazole or
methimazole: 50% decreased concentrations;
(h) induction of microsomal liver enzymes (phenytoin, bar-
biturates, rifampicin, carbamazepine): 30% to 50% de-
creased concentrations;
(i) inflammatory bowel disease: in some patients unpredict-
ably reduced concentrations due to malabsorption;
(j) prednisolone sodium tetrahydrophthalate: 50% de-
creased concentrations; some brands of enteric-coated
prednisolone: unpredictably reduced concentrations.
Conclusion
The patient we are discussing dramatà.ally demonstrates -the
clinical importance of the pharmacokinetics of cyclosporine and
prednisone in renal transplant recipients. She developed severe
oroesophageal moniliasis following treatment with high doses of
corticosteroids for an acute renal allograft rejection. Ketocon-
azole, given to treat the fungal infection, caused an inhibition of
the microsomal liver enzymes responsible for the degradation
of cyclosporine and prednisolone. As a consequence, the
patient had excess immunosuppression with retarded recovery
from the infection and exaggerated cyclosporine nephrotoxic-
ity. A more pronounced reduction of the cyclosporine dose
together with a reduction of the dose of prednisone must be
considered in patients given ketoconazole together with pred-
nisone and cyclosporine.
Renal function is an important determinant of the pharmaco-
kinetics of many water-soluble drugs. Therefore, altered renal
function is commonly considered for dose-finding in clinical
practice. Changes in liver function, on the other hand, are
rarely considered in prescribing medications despite the fact
that disease state and concurrent therapy can tremendously
increase or diminish the liver's capacity to metabolize xenobi-
otics, as exemplified by the inhibition of P-450 by ketoconazole
in the patient presented. The percentage reduction of the
metabolic clearance of metabolized drugs in patients with
severely impaired liver function can be comparable to the
percentage reduction of the renal clearance of drugs excreted
by the kidneys in patients with end-stage renal disease. Thus
one might anticipate that taking into account the factors respon-
sible for altered hepatic metabolism might improve our ability
to prescribe metabolized drugs in the future, just as our
consideration of renal function improved the dose-finding pro-
cess for water-soluble xenobiotics in the past.
Questions and answers
DR. JOHN T. HARRINGTON (Chief of Medicine, Newton-
Wellesley Hospital, Newton, Massachusetts): I understand that
erythromycin causes induction of the P-450 system but that the
enzymes induced are somehow immature. Could you please
clarify the effects of erythromycin?
DR. FREY: Macrolide antibiotics such as erythromycin are
potent inducers of P-450 isoenzymes [17, 18]. These isozymes
are not immature but function normally. Erythromycin not only
has the capacity to induce microsomal liver enzymes, but it is
also a potent inhibitor of some P-450 isozymes. As a conse-
quence of the inhibition of microsomal liver enzymes, cyclo-
sporine A concentrations increase when erythromycin is added
to cyclosporine A therapy in renal transplant patients [51].
DR. HARRINOTON: Dr. Frey, you commented at the onset of
your discussion that it would be desirable to have an interme-
diate biologic objective for cyclosporine. Could you tell us what
you think needs to be done to identify such intermediate
biologic objectives and what would be meaningful parameters
to be investigated for this purpose?
DR. FREY: The definition of an intermediate therapeutic
objective for immunosuppressive therapy is not only desirable
for cyclosporine A dosing but also for dose-finding of all other
immunosuppressive agents. Such a measure would be desir-
able, especially in patients given a combination of drugs, in many
transplant patients. The putative intermediate therapeutic objec-
-live -should be -of-predictwe value -for-the -final Therapeulic nhjec-
tive, which is absence of allograft rejection. Because the immu-
nologic network of allograft rejection has not been completely
elucidated, it is difficult for one to make a rational decision
concerning the definition of a parameter reflecting overall immu-
nosuppression. It is conceivable that measurements of soluble
cytokines might be useful for that purpose in the future. The fact
that not all the elements of the immunologic network have been
discovered does not preclude that one might find a simple measure
reflecting overall immunosuppression; as is well known, the
prothrombin time, an extraordinarily useful intermediate thera-
peutic objective for anticoagulation with coumadin, was discov-
ered long before the complex network of blood coagulation was
entirely understood.
DR. MARTIN COGAN (Chief, Division of Nephrology, Veter-
ans Administration Hospital, San Francisco, California): You
suggested that cyclosporine concentration measurements are
useful in assessing compliance and in the setting of complex
pharmacologic interactions. Are cyclosporine measurements of
any practical use in the more common clinical situations, such
as a decrease in glomerular filtration rate in the posttransplant
period?
DR. FREY: As I already mentioned, the methods used for
measuring blood concentrations of cyclosporine do not assess
the total concentrations of the biologically relevant cyclóspo-
rifle metabolites. Therefore, one might predict that the utility of
cyclosporine blood concentration measurements is of limited
value when compliance or absorption or metabolism of cyclo-
sporine is not grossly abnormal. With respect to the immediate
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posttransplant period, absorption and metabolism of cyclospo-
rifle A can be quite variable. In addition, during that time
period, many patients are not yet at steady state as far as
cyclosporine A concentrations are concerned. Therefore, fre-
quent monitoring of blood concentrations of cyclosporine A
during the posttransplant period might be appropriate. Please
note, however, that no formal trial has been set up to demon-
strate unambiguously the clinical utility of such measurements.
D. FLAvI0 VINCENTI (Professor of Medicine, University of
California, San Francisco): What should the clinician do when
faced with very low trough levels of cyclosporine early after
transplantation?
DR. FREY: First, increase the dose of cyclosporine A. If this
does not increase the blood concentrations, it might be reason-
able to administer cyclosporine A intravenously for some days
until the absorption of cyclosporine A is normalized. Systemic
availability of oral prednisone is less of a concern, so it might
also be reasonable to increase the dose of prednisone for some
days to have sufficient immunosuppression. I would not recom-
mend a formal pharmacokinetic assessment in the early post-
transplant period, because the parameters derived from such
measurements might not be of predictive value for the kinetics
in the same patient later.
DR. LESLIE Z. BENET (Chairman, Department of Pharmacy,
University of California, San Francisco): If increased gastroin-
testinal transit, that is, diarrhea, decreases cyclosporine ab-
sorption, why does metoclopramide increase cyclosporine area
under the curve [121?
DR. FREY: Metoclopramide is known to stimulate the gastric
emptying of isotype-labeled solid and liquid meals and has been
shown to increase the bioavailability of other drugs. The
mechanism for the increased bioavailability of xenobiotics
following the administration of metoclopramide is, to the best of
my knowledge, unknown.
DR. BENET: Dr. Frey, you already mentioned that the admin-
istration of food increases the cyclosporine A concentrations in
blood after oral dosing. We have recently investigated the
pharmacokinetics of cyclosporine A in healthy subjects follow-
ing administration of cyclosporine both orally and intrave-
nously without and with high-fat meals. Our findings corrobo-
rate previous studies in that the bioavailability of cyclosporine
was estimated to be 21% and 79%, when administered without
and with a high-fat meal, respectively. Surprisingly, blood and
plasma clearance of cyclosporine A increased after the admin-
istration of a high-fat meal. The most likely interpretation for
that finding is that changes in plasma lipid composition might
affect volume of distribution and clearance of cyclosporine A
[138].
It was suggested that many patients exhibit a second peak at
8 to 10 hours following oral dosing. Also, in some patients a
second peak of immunosuppressive effects has been found. Can
you confirm these observations?
DR. FREY: We have assessed the AUC of cyclosporine A (0
to 24 hours) in more than 80 instances. The blood concentra-
tions were determined by radioimmunoassay and high-perfor-
mance liquid chromatography. We cannot confirm the finding of
a second peak by our physicochemical measurements. Some of
the metabolites of cyclosporine A exhibit immunosuppressive
activity. The kinetics of these metabolites might be different
from the kinetics of the parent compound, and some of the
metabolites might not be assessed by the physico-chemical
methods used. Therefore it is conceivable that in some patients
a second peak of immunosuppressive effect was present, de-
spite the absence of such a peak, when cyclosporine was
measured by radioimmunoassay or high-performance liquid
chromatography.
DR. BENET: You used a specific assay to measure cyclospo-
rine A in the patient discussed here. Would you please com-
ment on the activity of cyclosporine A metabolites? Which ones
would you expect to be present in greater concentrations after
ketoconazole dosing?
DR. FREY: The administration of ketoconazole might change
the pattern of cyclosporine A metabolites generated and alter
the concentration ratios between these metabolites and the
parent compound. These ratios have not yet been determined,
so the interpretation of cyclosporine A measurements in pa-
tients taking ketoconazole is difficult. Assuming that the situa-
tion in mice is comparable to that in humans, it is likely that the
increased concentrations of cyclosporine A measured by high-
performance liquid chromatography are representative mea-
sures for the increased immunosuppressive activity after the
administration of ketoconazole together with cyclosporine A.
Indeed, Anderson and coworkers found that the blood concen-
trations of cyclosporine A doubled after the addition of keto-
conazole and that these higher cyclosporine A concentrations
were associated with a proportional reduction in the dose of
cyclosporine A required to obtain the same immunosuppressive
effect in vivo [49, 50].
DR. WILLIAM J.C. AMEND, JR. (Professor of Medicine,
University of California, San Francisco): Dr. Kahan of Hous-
ton suggests that pretransplant evaluation of cyclosporine ki-
netics is important for posttransplant cyclosporine dosing. How
do you react to this strategy?
DR. FREY: The basic assumption of the strategy is that the
absorption and metabolism of cyclosporine A are independent
of renal function and of the type of renal replacement therapy.
This might be true for many but not for all patients. In addition,
there is a practical limitation of that approach for most institu-
tions: in many transplant centers it is not feasible to perform a
complete pharmacokinetic assessment immediately before
transplantation.
Da. AMEND: Are there any measures similar to HbAlc for
glycemic control that could determine longer-teEm cyclosporine
dose compliance?
DR. FREY: That is an interesting thought. Unfortunately, we
don't know whether cyclosporine A is covalently bound to
some plasma or cellular constituents, as is the case for other
drugs [139].
DR. JOHN GAMBERTOGLIO (Professor of Pharmacy, Univer-
sity of California, San Francisco): Ketoconazole affects the
metabolism of cyclosporine A. Do other antifungal agents also
interfere with the metabolism of cyclosporine A or pred-
nisolone?
DR. FREY: Whether amphotericin B or fiucytosine affects the
disposition of cyclosporine A or prednisone is not known.
There are preliminary data indicating that fluconazole might
interfere to a lesser degree than does ketoconazole with the
metabolism of cyclosporine A [140, 141].
DR. CARLOS STEMPEL (Renal Fellow, University of Califor-
nia, San Francisco): First and coworkers demonstrated that the
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addition of ketoconazole reduced the amount of cyclosporine
required to achieve the same trough levels of cyclosporine and
suggested that this might be a way to lessen the cost of organ
transplantation [142]. Dr. Frey, could you comment on whether
such a strategy is appropriate?
DR. FREY: The patients in that study were treated with
prednisone, cyclosporine, ketoconazole, and azathioprine. Re-
nal transplant patients usually have hypertension and thus
require other drugs also. With the regimen proposed, most renal
transplant patients might end up taking at least 6 drugs, a
situation that jeopardizes compliance.
One reason for prescribing only a limited number of drugs to
a given patient is to enable the clinicians to relate drug and
effect. This might be difficult when ketoconazole is added,
because ketoconazole itself is immunosuppressive and dimin-
ishes the catabolism of prednisolone and methylprednisolone
and so might increase, unpredictably, the immunosuppressive
effect [46, 89, 143]. Another concern is ketoconazole-associated
liver injury; renal transplant patients exhibit impaired liver
function and are at increased risk of death from liver failure.
As First et al showed, the variability of pharmacokinetic
parameters for cyclosporine increases after the addition of
ketoconazole [142]. The range of the dose of cyclosporine used
to achieve the same blood concentrations of cyclosporine
increased from 3- to 4-fold, the range of the Cmax from 5- to
11-fold, and that of the "mean residence time" from 6- to
15-fold. This makes dosage adjustment more difficult in clinical
practice.
The introduction of cyclosporine has indeed increased the
costs of immunosuppression [1441. The overall cost-benefit
impact still might be favorable, however. The addition of
ketoconazole to cyclosporine might diminish the positive ben-
efits to patients that the introduction of cyclosporine has
yielded. For example, in First and colleagues' report, patients
given ketoconazole were required to make two or three clinic
visits per week for cyclosporine dose adjustment; one of the 17
patients treated with the combination had to discontinue taking
ketoconazole because of gastrointestinal side effects, and two
patients had rejections, probably related to ketoconazole,
which were successfully treated with a 10-day course of OKT3
(cost, without inpatient charges, about US $4000 each). With-
out a controlled trial taking into account both the medical and
the financial consequences, the prescription of a systematic
drug interaction between cyclosporine and ketoconazole cannot
be recommended. If First and colleagues wish to pursue their
therapeutic strategy, it might be worthwhile reducing the liver's
capacity to metabolize another drug of their triple therapy
(azathioprine) by adding allopurinol [145].
Ms. VICTORIA HALE (Medical student, University of Califor-
nia, San Francisco): You presented a very comprehensive list
of compounds that affect the metabolism of prednisolone and
cyclosporine. How do these compounds affect the metabolism
of each other?
DR. FREY: Cyclosporine and prednisolone are metabolized
by oxidases of the cytochrome P-450 system in the liver.
Therefore it is reasonable for us to assume that those two drugs
might interact at the level of those enzymes. As I already
mentioned, cyclosporine A does not affect the metabolism of
prednisolone. It is unknown whether prednisolone or methyl-
prednisolone interferes with the metabolism of cyclosporine A.
DR. HENRY HULTER (Associate Professor of Medicine, San
Francisco General Hospital, San Francisco): When oral pred-
nisone or intravenous prednisolone is administered, pred-
nisolone is found in three states in plasma: prednisolone bound
to transcortin, prednisolone bound to albumin, and free pred-
nisolone. What is the evidence that prednisolone bound to
plasma proteins is biologically inactive?
DR. FREY: Women taking oral contraceptive steroids have
more than a 100% higher concentration of prednisolone bound
to transcortin than do normal subjects [73]. When these plasma
samples containing various concentrations of prednisolone are
incubated with mixed lymphocyte cultures and the degree of
inhibition of the mixed lymphocyte reaction is quantified,
higher total concentrations of prednisolone are required to
produce half-maximal inhibition (EC50) of the lymphocytes in
women on oral contraceptive steroids than in controls. How-
ever, these concentration-response curves yield identical EC50
values when the unbound instead of the total concentration of
prednisolone is plotted. This finding suggests that the higher
transcortin-bound concentrations of prednisolone in women
taking estrogens are biologically unimportant in this specific
model. This conclusion is further supported by the observation
that patients with low transcortin concentrations (nephrotic
patients) have decreased EC50 values of total prednisolone
when the same model (mixed lymphocyte reaction) is used [73].
DR. MICHAEL HUMPHREYS (Chief, Division of Nephrology,
San Francisco General Hospital): The analysis of the concen-
tration-response curves between unbound concentrations of
prednisolone and inhibition of mixed lymphocyte cultures re-
vealed a shift to the left in nephrotic patients when compared
with healthy volunteers [73]. Such a shift might suggest the
presence of immunosuppressive substances in plasma of ne-
phrotic patients. For the concentration-response curves, the
same baseline was utilized. Therefore, these endogenous im-
munosuppressive substances must simulate the glucocorticoid
activity of unbound prednisolone. Is there more information
about the mechanism of the interaction between an endogenous
inhibitor and glucocorticoids?
DR. FREY: It has been known for more than 10 years that
nephrotic serum contains inhibitory components for allogene-
ically or lectin-stimulated lymphocytes. The physicochemical
properties of those agents have not been well defined, however.
Because purification of those agents is still missing, more
detailed interaction studies to assess the mechanism have not
been possible until now.
The observation that the biologic activity of a certain drug
level can be increased (and possibly also diminished) by endog-
enous compounds clearly indicates that a definition of a biologic
measure for overall immunosuppression in a given patient
would be of great help.
DR. D. UEI-JLINGER (Nephrologist, Davis Medical Center,
San Francisco): Does ketoconazole also affect the metabolism
of methylprednisolone, or is the interaction restricted to pred-
nisolone?
DR. FREY: Ketoconazole inhibits the metabolic clearance
rate of methylprednisolone in normal volunteers [143]. How-
ever, not all the P-450 isoenzymes involved in the metabolism
of methylprednisolone are also biologically relevant for the
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metabolism of prednisolone. For instance, macrolide antibiot-
ics, such as troleandomycin and erythromycin, inhibit methyl-
prednisolone metabolism but have no apparent effect on pred-
nisolone metabolism. The concept that the various isozymes of
the P-450 system have differential relevance for the metabolism
of prednisolone and methylprednisolone is supported by the
observation that induction of microsomal liver enzymes by
phenobarbital, carbamazepine, and phenytoin revealed differ-
ences in the degree of stimulation of the catabolism of pred-
nisolone and methyiprednisolone in children [1151.
DR. NICHOLAS V. HOLFORD (Professor of Medicine, Univer-
sity of Auckland, Auckland, New Zealand): It appears that you
are proposing that if one could easily employ a target concen-
tration strategy, you would recommend using that for pred-
nisolone but probably not for cyclosporine. Some data seem to
support the use of prednisolone, but I though you said the
cyclosporine trials had yet to be done. Can you clarify that? Do
you think that the trials should be performed for cyclosporine
A, or do you think that there is no point in attempting to use a
target concentration strategy for cyclosporine?
DR. FREY: It would be useful to perform a large trial to define
more precisely the relationship between blood concentrations
of cyclosporine and its efficacy and/or side effects in renal
transplant patients. Such a study would be useful even if the
result were negative, that is, in the absence of a relationship
between the present, non-perfect, measurements of cyclospo-
rifle in blood and biologic effect.
DR. GAMBERTOGLIO: When prednisone is given, one can
measure specifically unbound prednisolone in plasma. This is
the only metabolite that exhibits biologic activity. Therefore,
the most important prerequisite for a target concentration
strategy, namely, that one can measure specifically the biolog-
ically relevant compound, is fulfilled. For cyclosporine, on the
other hand, one cannot assess specifically the biologically
relevant metabolites. Yet cyclosporine A measurements are
widely used in clinical practice, whereas prednisolone measure-
ments for dose-finding are virtually never considered. As Dr.
Frey pointed out, this is largely due to the short half-life of
prednisolone. It might be useful to consider prednisolone mea-
surements by applying well-defined strategies for the timing of
plasma sample collection to utilize the specific measurements
available for prednisolone in clinical practice in the future.
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